These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1482 related items for PubMed ID: 12481013

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E.
    JOP; 2006 May 09; 7(3):283-94. PubMed ID: 16685109
    [Abstract] [Full Text] [Related]

  • 12. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W, Nofech-Mozes S, Kahn HJ.
    Breast J; 2007 May 09; 13(2):122-9. PubMed ID: 17319852
    [Abstract] [Full Text] [Related]

  • 13. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
    Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA.
    Cancer Res; 2002 Mar 15; 62(6):1676-81. PubMed ID: 11912139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ, Hyjek E, Early E, Knowles DM.
    Int J Surg Pathol; 2006 Oct 15; 14(4):279-84. PubMed ID: 17041191
    [Abstract] [Full Text] [Related]

  • 17. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Oct 15; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 18. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA, Navarro S, Noguera R, Almenar S, Pellin A, Vázquez C, Llombart-Bosch A.
    Arkh Patol; 2003 Oct 15; 65(1):50-5. PubMed ID: 12669615
    [Abstract] [Full Text] [Related]

  • 19. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.
    Hum Pathol; 2007 Feb 15; 38(2):197-204. PubMed ID: 17234468
    [Abstract] [Full Text] [Related]

  • 20. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.
    Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU.
    Histopathology; 2004 Apr 15; 44(4):332-8. PubMed ID: 15049898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.